Tumor suppression via inhibition of SWI/SNF complex-dependent NF-κB activation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Nuclear factor kappa B (NF-κB) is constitutively activated in many epithelial tumors.
• NF-κB inhibitors are limited in cancer therapy due to broad biological effects.
• d4-family proteins (DPF1, DPF2, DPF3a/b) act as adaptors linking NF-κB to the SWI/SNF complex.

Purpose of the Study:

• To investigate the potential of d4-family proteins as cancer therapy targets.
• To evaluate the inhibitory effects of a specific d4-family protein region (CT1) on tumor growth.
• To identify the role of CT1 in NF-κB activation and SWI/SNF complex function.

Main Methods:

• Exogenous expression of CT1 in epithelial tumor cell lines (A549, HeLaS3).
• In situ proximity ligation assay to assess adaptor function.
• Microarray analysis to identify NF-κB target genes affected by CT1.
• Mouse xenograft model to evaluate tumor formation suppression.

Main Results:

• Exogenous CT1 expression showed stronger inhibition of anchorage-independent growth than single d4-family protein knockdown.
• CT1 retains adaptor function, indicating C-terminal regions are crucial for SWI/SNF-dependent NF-κB activation.
• CT1 suppressed a subset of NF-κB target genes, including IL6, which contributes to anchorage-independent growth.
• CT1 expression suppressed tumor formation in a mouse xenograft model.

Conclusions:

• CT1 functions as a dominant-negative mutant of the d4-family proteins.
• d4-family proteins are promising targets for epithelial cancer therapy.
• Targeting the d4-family proteins offers a potential therapeutic strategy for cancers with NF-κB activation.